Compass Therapeutics (id:5364 CMPX)

1.49 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 11:35:14 AM)

Exchange closed, opens in 1 day 21 hours

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• All

About Compass Therapeutics

Market Capitalization 189.87M

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.